Matheson LLP's international focus and commitment to the life sciences sector has brought it a wealth of top clients in the pharmaceutical and medtech sectors, leading to a steady pipeline of transactional, corporate advisory and regulatory advisory instructions. It has continued to work on some of the highest value cross-border transactions in the sector The firm is also a healthcare litigation heavyweight, especially medical malpractice and product liability litigation, while also having a strong presence in healthcare transactions, including a number of recent hospital and nursing home deals. Litigator Rebecca Ryan is a leader in healthcare, disease and product liability cases. Kate McKenna is a key figure for life sciences regulatory matters, while David Fitzgibbon is at the forefront of life sciences M&A, along with John Coary. Emma Doherty specialises in corporate governance for both healthcare and life sciences businesses.
Legal 500 redaktioneller Kommentar
- Profil
- Soziale Medien
Kernmandanten
- Aerogen
- Agilent Technologies
- Arena Pharmaceuticals
- Astrix Technology
- BioIQ
- Bon Secours Mercy Health
- Centrient Pharmaceuticals
- Chemocentryx
- Ethypharm SAS
- Grifols
Highlight-Mandate
Advised on all aspects of the proposed acquisition of Horizon Therapeutics by Pillartree.
Advised Macquarie Asset Management in relation to its agreement to acquire the Beacon Hospital Group.
Advised Medlab and Sonic Healthcare Ireland, and their insurers, in relation to a number of complex and high value negligence actions arising from Cervical Check screening.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Praxisleitung
Rebecca Ryan; Emma Doherty; Kate McKenna
Weitere Kernanwält*innen
David Fitzgibbon; John Coary